Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants.

Conversely, differences in survival favoring M+/without PD patients exposed to olaparib were only of borderline significance ( n = 73, of whom 51 received platinum‐based first‐line chemotherapy; Figure S2A and Table S1 ) and did not significantly differ in patients who received olaparib in its current indication (first‐line maintenance in patients not progressing after platinum‐based chemotherapy, n = 60; Figure S2B ).

also in 483 other papers